Wang Jie, Ma Xiaoxi, Lu Jiaying, Wu Jie, Xiao Zhenxu, Zhang Huiwei, Bao Weiqi, Ding Saineng, Zheng Li, Liang Xiaoniu, Guan Yihui, Zuo Chuantao, Ding Ding, Zhao Qianhua
Department and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Alzheimers Dement. 2025 Jun;21(6):e70378. doi: 10.1002/alz.70378.
Despite advances in biomarker assessment, molecular neuroimaging, and disease-modifying therapies for cognitive disorders, China lacks well-characterized clinical cohorts integrating comprehensive clinical assessments and multimodal biomarkers.
The Shanghai Memory Study (SMS), an ongoing hospital-based cohort, enrolled participants undergoing clinical/neuropsychological assessments, genotyping, multimodal imaging, and biospecimen collection.
From 2012 to 2024, 2001 participants were enrolled: 115 cognitively unimpaired (CU), 938 with mild cognitive impairment (MCI), and 948 with dementia. Positron emission tomography (PET) scan revealed A+/T+ positivity rates of 15.8% in CU, 51.2% in MCI, and 100% in Alzheimer's disease dementia (ADD). Plasma tau phosphorylated at threonine 181 (p-tau181) level increased gradually across the AD continuum. Blood p-tau181 and 18F-Florzolotau PET showed comparable utility for amyloid status identification. In a subcohort of 251 amnestic MCI (aMCI) patients, low Aβ42/Aβ40 and elevated p-tau181 predicted 4.7-year ADD risk.
By offering an integrated framework, SMS will facilitate the exploration of AD pathogenesis and the understanding of cognitive disorders.
The SMS is an ongoing prospective cohort study based on a memory clinic in China. The SMS has established a relatively large-scale dataset that includes clinical data, biofluid markers, MRI and PET imaging, and novel biomarkers. By offering an integrated framework, SMS aims to facilitate the exploration of AD pathogenesis and deepen our understanding of cognitive disorders.
尽管在生物标志物评估、分子神经影像学以及认知障碍的疾病修饰治疗方面取得了进展，但中国缺乏整合了全面临床评估和多模态生物标志物且特征明确的临床队列。
上海记忆研究（SMS）是一项正在进行的基于医院的队列研究，纳入了接受临床/神经心理学评估、基因分型、多模态成像和生物样本采集的参与者。
从2012年到2024年，共纳入2001名参与者：115名认知未受损（CU）者、938名轻度认知障碍（MCI）者和948名痴呆患者。正电子发射断层扫描（PET）显示，CU组的A+/T+阳性率为15.8%，MCI组为51.2%，阿尔茨海默病痴呆（ADD）组为100%。苏氨酸181位点磷酸化的血浆tau（p-tau181）水平在整个AD连续谱中逐渐升高。血液p-tau181和18F- Florzolotau PET在淀粉样蛋白状态识别方面显示出相当的效用。在251名遗忘型MCI（aMCI）患者的亚队列中，低Aβ42/Aβ40和升高的p-tau181预测了4.7年的ADD风险。
通过提供一个综合框架，SMS将有助于探索AD发病机制并增进对认知障碍的理解。
SMS是一项正在进行的基于中国一家记忆诊所的前瞻性队列研究。SMS建立了一个相对大规模的数据数据集，包括临床数据、生物流体标志物、MRI和PET成像以及新型生物标志物。通过提供一个综合框架，SMS旨在促进对AD发病机制的探索并加深我们对认知障碍的理解。
